Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody.

Two patients with acute leukemia were treated with chemoradiotherapy and allogeneic bone marrow transplantation. Despite the prophylactic use of methotrexate after grafting, both patients developed severe graft-versus-host disease that was refractory to treatment with methylprednisolone. The graft-versus-host disease was then treated with a monoclonal antibody, 64.1, that reacts with a p19 antigen on human T cells. The disease responded dramatically to this treatment, but both patients subsequently developed a fatal polyclonal lymphoproliferative disorder arising in donor-derived B cells. Hybridization studies showed Epstein-Barr virus in both tumors. The combined effect of severe end-stage graft-versus-host disease and potent immunosuppressive therapy probably resulted in a progressive immunodeficiency syndrome that abrogated the T-cell-mediated surveillance mechanism that normally modulates the proliferation of Epstein-Barr-virus-infected B lymphocytes.

[1]  T. Starzl,et al.  REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.

[2]  R. Warnke,et al.  Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. , 1984, The New England journal of medicine.

[3]  H. Deeg,et al.  Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. , 1984, Human immunology.

[4]  E. Reinherz,et al.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex , 1983, The Journal of experimental medicine.

[5]  E. Reinherz,et al.  Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex , 1982, Cell.

[6]  A. Boyd,et al.  Two monoclonal anti-human T lymphocyte antibodies have similar biologic effects and recognize the same cell surface antigen. , 1982, Journal of immunology.

[7]  E. Reinherz,et al.  Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Hackman,et al.  A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. , 1982, Blood.

[9]  J. Kersey,et al.  PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION , 1982, The Lancet.

[10]  H. Balfour,et al.  Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. , 1982, The New England journal of medicine.

[11]  G. Janossy,et al.  USE OF ANTI-T-CELL MONOCLONAL ANTIBODY OKT3 TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA , 1982, The Lancet.

[12]  W. Henle,et al.  Expression of Epstein-Barr viral early antigen in monolayer tissue cultures after transfection with viral DNA and DNA fragments , 1981, Journal of virology.

[13]  I. Ernberg,et al.  T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. , 1981, Cancer research.

[14]  T. Seemayer,et al.  Epstein-Barr virus in a malignant lymphoproliferative disorder of B-cells occurring after thymic epithelial transplantation for combined immunodeficiency. , 1981, Cancer research.

[15]  J. Rosai,et al.  Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. , 1981, Cancer research.

[16]  W. Henle,et al.  Epstein-Barr virus-specific serology in immunologically compromised individuals. , 1981, Cancer research.

[17]  J. Pincott,et al.  Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by clinical, virological, and immunopathological studies. , 1981, Cancer research.

[18]  R. Colvin,et al.  Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. , 1981, The New England journal of medicine.

[19]  R. Storb,et al.  Treatment of graft‐versus‐host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids , 1981, American journal of hematology.

[20]  S. Hsu,et al.  A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. , 1981, American journal of clinical pathology.

[21]  T. Chang,et al.  Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Klein,et al.  Epstein-Barr-virus-carrying lymphoma in a patient with ataxia-telangiectasia. , 1981, British medical journal.

[23]  M. Lipinski,et al.  Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man , 1981, The Journal of experimental medicine.

[24]  E. Reinherz,et al.  A monoclonal antibody blocking human T cell function , 1980, European journal of immunology.

[25]  B. Lange,et al.  Epstein‐Barr virus‐related serology in marrow transplant recipients , 1980, International journal of cancer.

[26]  J. Robinson,et al.  Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. , 1980, The New England journal of medicine.

[27]  J. D. De Mey,et al.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. , 1980, Journal of immunology.

[28]  I. Magrath,et al.  Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. , 1979, The New England journal of medicine.

[29]  Guttmann Rd.  Renal transplantation (first of two parts). , 1979 .

[30]  E. Reinherz,et al.  Monoclonal antibodies defining distinctive human T cell surface antigens. , 1979, Science.

[31]  C. Taylor,et al.  Immunoblastic sarcoma in donor cells after bone-marrow transplantation. , 1979, The New England journal of medicine.

[32]  C. Jenkin,et al.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. , 1978, Immunochemistry.

[33]  R. Schwartz,et al.  Immunodeficiency and the pathogenesis of lymphoma and leukemia. , 1978, Seminars in hematology.

[34]  R. Storb,et al.  Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. , 1978, Transplantation proceedings.

[35]  M. Jondal,et al.  Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Klein,et al.  Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell lines , 1973, International journal of cancer.

[37]  T. Caspersson,et al.  Differential binding of alkylating fluorochromes in human chromosomes. , 1970, Experimental cell research.

[38]  F. Klein,et al.  An immunofluorescence procedure for the detection of intracellular immunoglobulins. , 1969, Clinical and experimental immunology.